Overview

Branded Generics Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027.

Transforming medical practices, increased profit margin, entry of emerging players, simple marketing authorization processes are some of the crucial factors responsible for the growth of the market. Branded generics are wither sold by the patented drug manufacturer or by generic manufacturers building up the brand’s equity for their generic medication products. The value-added generics can either be an advanced form of dosage of a patented drug or generic drug with a name. The generics industry is booming at an exponential rate and this acceptance by pharmacy chains functioning on a large-scale which has proven to be a crucial factor for the branded generics market growth.

Market Segmentation:

By Product Type
•    Trade-Named Generics 
•    Value-Added Branded Generics
By Application
•    Cardiovascular Drugs
•    Anti-Cancer Drugs
•    CNS Drugs
•    Anti-Infective Drugs
By Distribution channel
•    Hospital Pharmacy
•    Online Pharmacy
•    Clinics 
•    Drug Stores
By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

The market is fragmented into product type, application, distribution channel and region. The product type segment is categorised into trade named generics, value-added branded generics. The value-added branded generics segment is anticipated to branded generics market share as they are generally developed with advanced pharma technologies. These technologies have resulted in the development of patient-friendly products that meet the bio-equivalency requirements and maintaining the same efficacy, safety and quality as the original drug. The application segment is divided into cardiovascular drugs, anti-cancer, CNS and anti-infective drugs. The cardiovascular drugs segment is predicted to lead the market owing to the expiration of many CVS drugs. The distribution channel segment is diversified into hospital pharmacy, online pharmacy, clinics and drug stores.

Regional Analysis:

The North America region is predicted to dominate the market during the forecast period, and this is mainly owing to rising insistence for cost-effective drugs. Generic drug supply industry is competitive in Canada over a decade. The Europe region is second to the North America region in terms of market growth owing to key players targeting European markets where the treatments are inexpensive. 

Competitive Landscape:                            

Some of the prominent market players are Eva Pharmaceutical Industries Ltd, Mylan N.V., Hospira Inc., Dr. Reddy’s Laboratories Ltd., Apotex Inc., GlaxoSmithKline Pharmaceuticals Limited, Valeant, ZydusCadila, Sandoz, Lupin Pharmaceuticals Inc., Par Pharmaceutical Companies Inc., Sanofi, AstraZeneca. 

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global branded generics market by product type, by application, by distribution channel and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
         1.1 Objectives of the Study 
         1.2 Market Definition 
         1.3 Market Scope 
                1.3.1 Years Considered for the Study
                1.3.2 Market Covered
         1.4 Currency
         1.5 Limitations 
         1.6 Stakeholders     
2. Research Methodology 
          2.1 Research Data 
                2.1.1 Secondary Data
                          2.1.1.1 Key Data from Secondary Sources
                2.1.2 Primary Data
                          2.1.2.1 Key Data from Primary Sources
          2.2 Market Size Estimation 
          2.3 Market Breakdown and Data Triangulation 
          2.4 Assumptions for the Study  
3. Executive Summary
          3.1 Market Outlook
          3.2 Segment Outlook
          3.3 Competitive Insights
4. Market Variables, Trends & Scope
          4.1 Market Lineage Outlook
          4.2 Penetration and Growth Prospect Mapping
          4.3 Industry Value Chain Analysis
          4.4 Cost Analysis Breakdown
          4.5 Technology Overview
          4.6 Regulatory Framework on Country Level
                4.6.1 Reimbursement Framework    
                4.6.2 Standards and Compliances
5. Market Overview
          5.1 Market Dynamics
                5.1.1 Market Driver Analysis         
                5.1.2 Market Restraint Analysis         
                5.1.3 Industry Challenges                   
6. Market Analysis tools                       
          6.1 Industry Analysis - Porter’s
                     6.1.1 Supplier Power
                     6.1.2 Buyer Power
                     6.1.3 Substitution Threat
                     6.1.4 Threat from new entrants
                     6.1.5 Competitive Rivalry                  
          6.2 Pestel Analysis
                     6.2.1 Political Landscape
                     6.2.2 Environmental Landscape
                     6.2.3 Social landscape
                     6.2.4 Technology landscape
                     6.2.5 Legal Landscape
7. Branded Generics Market, By Product Type Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
          7.1 Trade-Named Generics 
          7.2 Value-Added Branded Generics                         
8. Branded Generics Market, By Application Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
          8.1 Cardiovascular Drugs
          8.2 Anti-Cancer Drugs
          8.3 CNS Drugs
          8.4 Anti-Infective Drugs    
9. Branded Generics Market, By Distribution Channel Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
          9.1 Hospital Pharmacy
          9.2 Online Pharmacy
          9.3 Clinics 
          9.4 Drug Stores
10. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          10.1. Introduction
          10.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                10.2.1. U.S.
                10.2.2. Canada
                10.2.3. Mexico 
                10.2.4. Rest of North America
          10.3 Market Size (USD Mn) Forecast for North America 2020-2027
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          11.1. Introduction
          11.2. Regional Market Trends
          11.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
                11.3.1. Brazil
                11.3.2. Venezuela
                11.3.3. Argentina
                11.3.4. Rest of Latin America
          11.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          12.1. Introduction
          12.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
                12.2.1. Germany
                12.2.2. U.K
                12.2.3. France
                12.2.4. Italy
                12.2.5 Switzerland
                12.2.6. Spain
                12.2.7. Russia
                12.2.8. Poland
                12.2.9. Rest of Western Europe
          12.3 Market Size (US$ Mn) Forecast for Europe 2020-2027
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          13.1 Introduction
          13.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                 13.2.1 Japan
                 13.2.2 China
                 13.2.3 Singapore
                 13.2.4 Korea         
                 13.2.5 India
                 13.2.6 Australia and New Zealand
                 13.2.7 ASEAN
                 13.2.8 Rest of Asia Pacific
          13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    14.1 Introduction
    14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
        14.2.1 UAE
        14.2.2 South Africa
        14.2.3 Egypt
        14.2.4 Saudi Arabia
        14.2.5 Rest of MEA
    14.3 Market Size (US$ Mn) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    15.1 Eva Pharmaceutical Industries Ltd
            15.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.1.2. Product Portfolio
               15.1.3. SWOT Analysis
            15.1.4. Financial Overview
                15.1.5. Strategic Overview
    15.2 Mylan N.V.
              15.2.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.2.2. Product Portfolio
              15.2.3. SWOT Analysis
              15.2.4. Financial Overview
              15.2.5. Strategic Overview
    15.3 Hospira Inc.
              15.3.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.3.2. Product Portfolio
              15.3.3. SWOT Analysis
              15.3.4. Financial Overview
              15.3.5. Strategic Overview
    15.4 Dr. Reddy’s Laboratories Ltd.
             15.4.1. Company Overview (HQ, Business Segments, Employee Strength)
             15.4.2. Product Portfolio
             15.4.3. SWOT Analysis
             15.4.4. Financial Overview
             15.4.5. Strategic Overview
    15.5 Apotex Inc.
              15.5.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.5.2. Product Portfolio
              15.5.3. SWOT Analysis
              15.5.4. Financial Overview
              15.5.5. Strategic Overview
    15.6 GlaxoSmithKline Pharmaceuticals Limited
              15.6.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.6.2. Product Portfolio
              15.6.3. SWOT Analysis
              15.6.4. Financial Overview
              15.6.5. Strategic Overview
    15.7 Valeant
             15.7.1. Company Overview (HQ, Business Segments, Employee Strength)
             15.7.2. Product Portfolio
             15.7.3. SWOT Analysis
             15.7.4. Financial Overview
             15.7.5. Strategic Overview
    15.8 ZydusCadila
              15.8.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.8.2. Product Portfolio
              15.8.3. SWOT Analysis
              15.8.4. Financial Overview
              15.8.5. Strategic Overview    
    15.9 Sandoz
              15.9.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.9.2. Product Portfolio
              15.9.3. SWOT Analysis
              15.9.4. Financial Overview
              15.9.5. Strategic Overview
    15.10 Lupin Pharmaceuticals Inc.
              15.10.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.10.2. Product Portfolio
              15.10.3. SWOT Analysis
              15.10.4. Financial Overview
              15.10.5. Strategic Overview
    15.11 Par Pharmaceutical Companies Inc.
              15.11.1. Company Overview (HQ, Business Segments, Employee Strength)
              15.11.2. Product Portfolio
              15.11.3. SWOT Analysis
              15.11.4. Financial Overview
              15.11.5. Strategic Overview
    15.12 Sanofi
             15.12.1. Company Overview (HQ, Business Segments, Employee Strength)
             15.12.2. Product Portfolio
             15.12.3. SWOT Analysis
             15.12.4. Financial Overview
             15.12.5. Strategic Overview
    15.13 AstraZeneca
            15.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.13.2. Product Portfolio
            15.13.3. SWOT Analysis
            15.13.4. Financial Overview
            15.13.5. Strategic Overview
16. Impact of COVID-19
      16.1. Positive influence on the healthcare industry
      16.2. The financial disruption of the manufacturing sector
      16.3. Impact of COVID-19 on emerging companies
      16.4. Significant mandates in the healthcare regulations initiated by administrations
      16.5. The overall economic slowdown of the developing and developed nations
17. Competitive Intelligence and Competitive Matrix
      17.1 Competitive Intelligence
      17.2 Competitive Matrix
18. Major Deals and Strategic Alliances Analysis
      18.1 Joint ventures
      18.2 Mergers and acquisitions              
      18.3 Licensing and partnerships
      18.4 Technology Collaborations
      18.5 Strategic Divestments
      18.6 Market Entry Strategies                        
19. Relevant Case Studies and Latest News Updates
20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics 

Tables

Figures